--- title: "Minerva Neurosciences (NERV) news: offering" url: "https://aibio.space/companies/minerva-neurosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NERV offering news: Minerva sets up $75 million at-the-market stock sale with Leerink Partners. Minerva Neurosciences, Inc (NASDAQ: NERV), United States." --- NERV Minerva Neurosciences, Inc NASDAQ · United States # Minerva Neurosciences (NERV) news NERV offering news Company Updates · 2026-08-07 ## [Minerva Neurosciences reports second quarter 2026 results and C19 trial progress](https://aibio.space/news/minerva-neurosciences-reports-second-quarter-2026-results-c19-trial/) Minerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026. ## Latest Minerva Neurosciences news 1. 2026-06-03 Company Updates [Minerva stockholders approve charter changes on officer liability and forum](https://aibio.space/news/minerva-stockholders-approve-charter-changes-officer-liability-forum/) At its June 3, 2026 annual meeting, Minerva's stockholders approved two charter amendments, and the board adopted amended bylaws the same day. 2. 2026-05-27 Financings [Minerva sets up $75 million at-the-market stock sale with Leerink Partners](https://aibio.space/news/minerva-sets-up-75-million-market-stock-sale-leerink-partners/) Minerva signed a sales agreement with Leerink Partners LLC for up to $75.0 million of common stock, and its filing also says the roluperidone Phase 3 relapse phase now runs 52 weeks. 3. 2026-05-05 Company Updates [Minerva reports first quarter 2026 results and starts its Phase 3 trial](https://aibio.space/news/minerva-reports-first-quarter-2026-results-starts-phase-3-trial/) The company reported a GAAP net loss of $125.4 million for the quarter, including a $109.4 million non-cash warrant charge, and said the first patient was screened in March. 4. 2025-10-22 Financings [Minerva Neurosciences agrees to $80 million private placement, up to $200 million with warrants](https://aibio.space/news/minerva-neurosciences-agrees-80-million-private-placement-up-200/) Vivo Capital LLC led the deal, which brings $80 million upfront in Series A preferred stock. The rest comes from two warrant tranches, and the larger one is tied to a Phase 3 roluperidone trial meeting its primary endpoint. 5. 2025-03-19 Listings [Minerva Neurosciences keeps Nasdaq listing after meeting $500,000 net income rule](https://aibio.space/news/minerva-neurosciences-keeps-nasdaq-listing-after-meeting-500-000-net/) Minerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital. ## Minerva Neurosciences at a glance - **Ticker**: NERV - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $75.3 million ### Related companies - [HARD TO TREAT DISEASES INC](https://aibio.space/companies/hard-to-treat-diseases/) OTC: HTDS - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) NASDAQ: IMMX - [Cytokinetics](https://aibio.space/companies/cytokinetics/) NASDAQ: CYTK - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) NASDAQ: VTVT - [Veradermics](https://aibio.space/companies/veradermics/) NYSE: MANE - [Adial Pharmaceuticals](https://aibio.space/companies/adial-pharmaceuticals/) NASDAQ: ADIL - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON ### Also on NASDAQ - [Structure Therapeutics](https://aibio.space/companies/structure-therapeutics/) GPCR - [Legend Biotech](https://aibio.space/companies/legend-biotech/) LEGN - [Rani Therapeutics Holdings](https://aibio.space/companies/rani-therapeutics/) RANI - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) REGN - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) SYRE - [Alpha Tau Medical](https://aibio.space/companies/alpha-tau-medical/) DRTS ## Minerva Neurosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | | Net income (loss) | [-$293.4 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | | Cash from operations | [-$13.5 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | [-$19.6 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | | Cash and equivalents | [$82.3 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526339171/) | [$21.4 million](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $24.7 million, plus short-term investments of $50.6 million, $75.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Minerva Neurosciences Has Minerva Neurosciences raised money recently? Our latest story on this, dated May 27, 2026: "Minerva sets up $75 million at-the-market stock sale with Leerink Partners". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/minerva-sets-up-75-million-market-stock-sale-leerink-partners/). What is the ticker symbol of Minerva Neurosciences? Minerva Neurosciences, Inc trades under the ticker NERV on NASDAQ. Where is Minerva Neurosciences listed? Minerva Neurosciences, Inc is listed on NASDAQ. Our directory also records these other listings: GETTEX:4MNA; LS:A3DMH5; LSX:A3DMH5. What is the SEC CIK of Minerva Neurosciences? The SEC Central Index Key (CIK) for Minerva Neurosciences, Inc is 1598646. Its filings are on SEC EDGAR. How many shares does Minerva Neurosciences have outstanding? 47,747,559 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Minerva Neurosciences listed under? Our directory records Minerva Neurosciences, Inc under United States. What does Minerva Neurosciences do? Our directory classifies Minerva Neurosciences, Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Minerva Neurosciences? The ISIN recorded for Minerva Neurosciences, Inc is US6033802058. Does aibio.space cover Minerva Neurosciences? aibio.space lists Minerva Neurosciences, Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Minerva Neurosciences incorporated? SEC records list its state or country of incorporation as MA. Is Minerva Neurosciences profitable? Minerva Neurosciences, Inc reported a net loss of $293.4 million for the fiscal year ended Dec 31, 2025, and used $13.5 million of cash in operations, per its annual report to the SEC. How much does Minerva Neurosciences spend on research and development? $5.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Minerva Neurosciences have? $75.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Minerva Neurosciences (NERV) stock news? Our latest story on Minerva Neurosciences, dated Aug 7, 2026: "Minerva Neurosciences reports second quarter 2026 results and C19 trial progress". Minerva reported GAAP net income of $17.5 million for the quarter, driven by a non-cash warrant gain, and cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026. [Source](https://aibio.space/news/minerva-neurosciences-reports-second-quarter-2026-results-c19-trial/). Is Minerva Neurosciences at risk of delisting? Our latest listing story, dated Mar 19, 2025: "Minerva Neurosciences keeps Nasdaq listing after meeting $500,000 net income rule". Minerva keeps its Nasdaq listing on a net income test, not an equity test, and now faces a one-year panel monitor. The company reported $21.5 million in cash at the end of 2024 and says it will need more capital. [Source](https://aibio.space/news/minerva-neurosciences-keeps-nasdaq-listing-after-meeting-500-000-net/). ## Investor discussion: Minerva Neurosciences Members talk about Minerva Neurosciences (NERV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Minerva Neurosciences, newest first. Each line links the filing it comes from. 1. 2026-05-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1598646/000119312526241915/d136925d424b5.htm) 2. 2025-11-19 Financings Reported a financing. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/d48648dex991.htm) 3. 2025-10-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1598646/000119312525245552/d28380dex991.htm) 4. 2025-03-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1598646/000119312525057901/d841978d8k.htm) 5. 2025-01-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1598646/000119312525005042/d906093d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NERV on TradingView](https://www.tradingview.com/symbols/NASDAQ-NERV/). ## SEC filings and registration - **SEC name**: Minerva Neurosciences, Inc. - **CIK**: 1598646 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NERV (Nasdaq) - **State or country of incorporation**: MA - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803 - **Phone**: 617-600-7373 - **Shares outstanding**: 47,747,559 as of 2026-08-04 (10-Q filed 2026-08-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526346817/d116503d8k.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000119312526339171/nerv-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348d8k.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526257379/d57321d8k.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/d119518d8k.htm) filed 2026-05-27 - [424B5](https://www.sec.gov/Archives/edgar/data/1598646/000119312526241915/d136925d424b5.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000119312526205182/nerv-20260331.htm) filed 2026-05-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/d947378d8k.htm) filed 2026-05-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001598646), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Minerva Neurosciences, Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NERV, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Minerva Neurosciences, Inc - **Ticker**: NERV - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6033802058 - **Other listed symbols**: GETTEX:4MNA; LS:A3DMH5; LSX:A3DMH5 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NERV/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/minerva-neurosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Minerva Neurosciences (NERV) news: offering", 2026-10-31, https://aibio.space/companies/minerva-neurosciences/